MediPharm Labs (TSX:LABS) Debt-to-Revenue : 0.06 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is MediPharm Labs Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

MediPharm Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$2.23 Mil. MediPharm Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.07 Mil. MediPharm Labs's annualized Revenue for the quarter that ended in Dec. 2023 was C$36.52 Mil. MediPharm Labs's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.06.

MediPharm Labs Debt-to-Revenue Historical Data

The historical data trend for MediPharm Labs's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediPharm Labs Debt-to-Revenue Chart

MediPharm Labs Annual Data

Trend

Sep17

Sep18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

0.08

0.51

0.01

0.03

0.07

MediPharm Labs Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															0.03	0.01	0.08	0.08	0.06

Competitive Comparison of MediPharm Labs's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, MediPharm Labs's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MediPharm Labs's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MediPharm Labs's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where MediPharm Labs's Debt-to-Revenue falls into.

MediPharm Labs Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

MediPharm Labs's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(2.226	+	0.069)	/	33.062
	=	0.07

MediPharm Labs's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(2.226	+	0.069)	/	36.524
	=	0.06

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

MediPharm Labs Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of MediPharm Labs's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

MediPharm Labs (TSX:LABS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MediPharm Labs Corp (TSX:LABS) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

MEDIF:USA MLZ:Germany

Address

151 John Street, Barrie, ON, CAN, L4N 2L1

Website

https://www.medipharmlabs.com

MediPharm Labs Corp is a pharmaceutical company specializing in precision-based cannabinoids. The Company operates in one reportable segment, the production and sales of cannabis extracts and derivative products. Through its wholesale and white-label platforms, MediPharm Labs formulates, develops, processes, packages, and distributes cannabis extracts and cannabinoid-based products to domestic and international markets. Geographically company has a presence in Canada, Australia, Germany, and other countries and the majority of revenue derives from Canada.

Executives

Keith Strachan

Director